Repligen(US:RGEN)2025-10-28 11:33Revenue Performance - Q3 2025 revenue reached $189 million, representing a year-over-year increase of 22% and 18% organic growth[5] - Year-to-date 2025 revenue totaled $540 million, compared to $467 million for the same period in 2024, indicating a strong performance[6] - Full-year revenue guidance has been raised to a range of $729 million to $737 million, reflecting 14% to 15.5% year-over-year non-COVID organic growth[5] - All franchises experienced double-digit year-over-year revenue growth, with consumables and capital equipment revenues growing over 20%[6] - Total revenue for Q3 2025 reached $188.8 million, a 22% increase compared to $154.9 million in Q3 2024[20] - Organic revenue growth (non-GAAP) for Q3 2025 was 18%, up from 7% in Q3 2024[21] Profitability Metrics - GAAP gross profit for Q3 2025 was $101 million, compared to $77 million in Q3 2024, with a gross margin of 53.2%[6][8] - Adjusted earnings per share for Q3 2025 was $0.46, compared to $0.43 in the prior year[7] - The company reported a GAAP net income of $15 million for Q3 2025, compared to a loss of $1 million in Q3 2024[6] - Net income for Q3 2025 was $14.9 million, compared to a net loss of $0.7 million in Q3 2024[20] - Basic earnings per share (GAAP) for Q3 2025 was $0.27, compared to a loss of $0.01 in Q3 2024[20] - Adjusted net income (non-GAAP) for the nine months ended September 30, 2025, was $69.3 million, compared to $63.7 million for the same period in 2024[22] - Adjusted EBITDA for Q3 2025 reached $35.928 million, up from $32.005 million in Q3 2024, indicating a year-over-year increase of approximately 9.0%[24] Expenses and Costs - Cost of Goods Sold (GAAP) for Q3 2025 was $88.290 million, an increase from $77.383 million in Q3 2024, reflecting a rise of about 14.7%[25] - R&D expenses for Q3 2025 totaled $14.175 million, up from $9.710 million in Q3 2024, marking a year-over-year increase of approximately 46.5%[26] - SG&A expenses (GAAP) for Q3 2025 were $73.663 million, slightly down from $75.610 million in Q3 2024, indicating a decrease of about 2.6%[26] Cash and Assets - Cash and cash equivalents at September 30, 2025, were $749 million, slightly down from $757 million at the end of 2024[8] - Cash and cash equivalents as of September 30, 2025, were $748.7 million, slightly down from $757.4 million at the end of 2024[20] - Total assets increased to $2.92 billion as of September 30, 2025, from $2.83 billion at the end of 2024[20] Guidance and Projections - Guidance for net income (GAAP) for the year ending December 31, 2025, is projected between $46.500 million and $48.000 million[27] - Adjusted net income (Non-GAAP) guidance for the same period is expected to be between $93.500 million and $95.000 million[27] - Diluted earnings per share (GAAP) guidance for 2025 is estimated to be between $0.82 and $0.85[28] - Adjusted diluted earnings per share (Non-GAAP) guidance for 2025 is projected to be between $1.65 and $1.68[28] Strategic Developments - A strategic partnership with Novasign was announced to integrate digital twin capabilities into Repligen filtration systems[6] - The SoloVPE® PLUS product launch contributed to a record quarter for Process Analytics equipment placements[6] Operating Metrics - The operating (EBIT) margin for Q3 2025 was 8.9%, compared to a negative margin of 5.1% in Q3 2024[22] - Adjusted income from operations (non-GAAP) for Q3 2025 was $26.8 million, compared to $23.1 million in Q3 2024[22] - The company reported a total of 56.5 million diluted weighted average common shares outstanding for Q3 2025[20] - Adjusted Gross Margin (Non-GAAP) for Q3 2025 was 53.3%, compared to 50.7% in Q3 2024, showing an improvement of 2.6 percentage points[25]